

# silenceworks


BENITEC'S PROGRESS IN SILENCE

## Snapshot

Market Data	As at Oct 7, 2013
ASX code:	BLT
Market Cap:	31.07 million
52 Week High/Low:	\$0.275 - \$0.52*
Shares on issue:	83.96 million
Industry sector:	Biotechnology
* Converted to post consolidation pricing	

### In this issue

- ▶ CEO & MD Peter French: The reluctant CEO looks back
- ▶ Lodge Partners: Benitec has advantage over Arrowhead but is extremely undervalued
- ▶ Bioshares picks Benitec in Top 10 in Biotech Bull Market
- ▶ Benitec's cancer collaboration wins UNSW Innovation Award
- ▶ Benitec's Dr David Suhy presents at International Symposium on Hepatitis C in Melbourne.
- ▶ Benitec cements Investor and Public Relations



### CEO & MD Peter French: The reluctant CEO looks back

Dr Peter French joined Benitec in 2009 as Chief Scientific Officer when the company had just one and half employees, a mostly departing board and its key patents for ddRNAi under review by the US Patent Office. In August, 2013, Peter was invited to join the Board as Managing Director. In this frank interview, he looks back at the lowlights and highlights of the last four years. [Read the full story](#) ▶




### Lodge Partners: Benitec has advantage over Arrowhead but is extremely undervalued

In August, Lodge Partners compared Benitec and Arrowhead, a NASDAQ-listed biotech, whose announcement of clinical trials for its Hep B drug sparked a 108% increase in share price. Lodge anticipates a rise for Benitec, too, when it commences clinical trials for its Hep C drug, noting that Benitec has a higher value target, a technological advantage and is, by comparison, 'extremely cheap'. [Read the full report](#) ▶



### Bioshares picks Benitec in Top 10 Biotech Bull Market

In its September Biotech Bull Market Special Edition, Bioshares included Benitec in its Top 10 Picks along with only 2 other drug companies. Bioshares noted that Benitec was a high risk play, but with even higher value if clinical trials proceed and prove efficacy of ddRNAi with no safety issues; also that these three milestones will be significant value creation points for the company. [Read the full report](#) ▶



### Benitec's cancer collaboration wins UNSW Innovation Award

In September, Benitec and the Children's Cancer Institute of Australia were awarded the People's Choice Award at the University of NSW Innovation Awards, for their collaborative program to treat chemotherapy resistance in lung cancer. The overall winner was UNSW Vision Prosthetics Group for its bionic eye implant to restore sight to the blind. [Read the full story](#) ▶



### Benitec's Dr David Suhy presents at International Symposium on Hepatitis C in Melbourne.

This week, Dr David Suhy, Benitec's Senior Vice President Research & Development, spoke at the prestigious [International Symposium on Hepatitis C Virus and Related Viruses](#) (HCV 2013) in Melbourne. He presented Benitec's pre-clinical evaluation results for Benitec's lead drug, TT-034 for Hepatitis C. Read the abstract [here](#) and full presentation [here](#). Dr Suhy will also present his results to [The American Association for the Study of Liver Disorders](#) (AASLD) next month in Washington (DC).



### Benitec cements Investor and Public Relations in Australia

In a national road show this month, CEO and MD Peter French and CBO Carl Stubbings updated investors, potential investors, analysts and biotech industry representatives on Benitec's unique technology, its wide application and its rapid progress to the clinic. Read the presentation [here](#). Concluding the tour, Peter and Carl provided Boardroom Media with an audio version of the presentation and answered frequently asked questions. [Listen to webcast here](#).